Population-level genome sequencing reveals distinct Mycobacterium tuberculosis intrahost mutational trajectories in simian immunodeficiency virus co-infected and antiretroviral treated non-human primates

This study utilizes population-level whole-genome sequencing of *Mycobacterium tuberculosis* in non-human primates to reveal distinct intrahost mutational trajectories and increased bacterial diversification driven by SIV coinfection and antiretroviral therapy, highlighting specific selection pressures on lipid metabolism and oxidative damage response genes.

The Gist

The Big Picture: A Microscopic Detective Story

Imagine Tuberculosis (TB) not just as a disease, but as a master spy trying to infiltrate a fortress (the human body). Usually, the fortress has guards (the immune system) that try to stop the spy. But what happens if the guards are tired, confused, or taking medication that changes how they work?

This study is like a high-tech surveillance operation. The scientists didn't just look at one spy; they tracked thousands of TB bacteria inside 20 monkeys (non-human primates). They wanted to see how the bacteria changed (mutated) when the "guards" were compromised by a virus similar to HIV (SIV) or when the monkeys were treated with HIV medication (ART).

The Setup: The "Barcoded" Spy Network

To make sense of the chaos, the researchers used a clever trick. They gave the TB bacteria barcodes (like unique QR codes).

• The Experiment: They infected the monkeys with a library of these barcoded bacteria.
• The Twist: Some monkeys had a healthy immune system. Some had the SIV virus (weakening their immune system). Some had SIV but were on medication (ART) that suppressed the virus.
• The Investigation: After a few weeks, they took samples from over 480 different spots in the monkeys' bodies (lungs, lymph nodes, etc.). They sequenced the DNA of the bacteria in every single spot to see how the "spies" had changed.

Key Findings: What the Spies Learned

1. The "Wild West" Effect (SIV Infection)

The Analogy: Imagine a city where the police force is on strike.
The Finding: In the monkeys infected with SIV (the virus), the TB bacteria were evolving much faster.

• Why? Because the immune system was too weak to kill off the bacteria quickly. The bacteria had more time to reproduce, and every time they copied their DNA, they made mistakes (mutations). It was like a factory running wild without a quality control manager, churning out many slightly different versions of the product.

2. The "Oxidative Stress" Trap (ART Treatment)

The Analogy: Imagine the police are back on duty, but they are using a very aggressive, scorched-earth tactic that burns everything down, including the buildings.
The Finding: In the monkeys that had SIV but were on ART (medication), the bacteria didn't just mutate randomly. They showed a specific pattern of damage: oxidative damage.

• Why? Even though the virus was suppressed, the immune system seemed to be "over-reacting" or dysregulated. It was attacking the bacteria with chemical weapons (oxidative stress) that left specific scars on the bacteria's DNA. It's as if the immune system was so angry it was burning the spies' fingerprints, leaving a distinct trail of "C>T" mutations.

3. The "Traveling Salesman" Map (Dissemination)

The Analogy: Imagine a family tree, but instead of people, it's bacteria spreading from one room to another.
The Finding: By combining the original "barcodes" with the new DNA mutations, the scientists could draw a map of exactly how the bacteria traveled.

• They saw that the bacteria didn't just spread from the lungs to everywhere at once. Instead, they spread in parallel sub-networks.
• Example: A bacterium might mutate in the lung, travel to a lymph node, mutate again, and then travel to the liver. By tracking these tiny DNA changes, the scientists could reconstruct the exact journey the bacteria took, like following a breadcrumb trail.

4. The "Survival Kit" (Lipid Metabolism)

The Analogy: If you are stranded on an island, you learn to eat whatever is available, even if it's weird.
The Finding: The bacteria kept mutating in genes related to eating fats (lipids).

• The human body is full of fats. The TB bacteria are learning how to break down and eat these fats to survive.
• Interestingly, the mutations the monkeys' bacteria developed were strikingly similar to mutations found in human TB patients. This suggests that TB has a universal "survival kit" for dealing with human bodies, regardless of whether the host is a monkey or a human.

Why Does This Matter?

1. HIV and TB are a Deadly Duo: This study proves that having HIV (or SIV in monkeys) changes the rules of the game. It allows TB to evolve faster and potentially become harder to treat.
2. Medication Has Side Effects: Even when HIV medication works perfectly to stop the virus, it might leave the immune system in a weird state where it attacks TB in a way that causes specific DNA damage. This could influence how TB evolves in the future.
3. The "Fat" Connection: The fact that TB keeps mutating to eat fats suggests that targeting these specific fat-eating pathways could be a new way to kill the bacteria, regardless of drug resistance.

The Bottom Line

This research is like watching a movie in slow motion. By looking at the DNA of TB bacteria in hundreds of different body parts, the scientists saw that the immune system's condition (healthy, weakened by virus, or medicated) directly shapes how the bacteria evolve.

• Weak Immune System (SIV): Bacteria multiply fast and make random mistakes.
• Medicated Immune System (ART): Bacteria get battered by chemical attacks, leaving specific scars.
• The Result: TB is a master adapter, constantly rewriting its own instruction manual to survive the specific environment of its host. Understanding these changes helps us design better drugs to stop it.

Technical Summary

1. Problem Statement

Tuberculosis (TB) remains a leading cause of death globally, particularly among people living with HIV (PLHIV). While antiretroviral therapy (ART) suppresses HIV and reduces TB mortality, PLHIV on long-term ART still face elevated risks of active TB disease despite viral control and stable CD4 counts. The mechanisms driving this increased susceptibility and the impact of HIV/ART on the evolutionary landscape of Mycobacterium tuberculosis (Mtb) within the host remain unclear. Specifically, it is unknown how SIV (the simian model for HIV) coinfection and ART treatment alter Mtb mutation rates, types of DNA damage, and bacterial dissemination patterns. Furthermore, previous studies were limited to accessible sites (e.g., sputum), potentially missing the full diversity of Mtb populations in extrapulmonary tissues.

2. Methodology

The study utilized a comprehensive population-based whole-genome sequencing (WGS) approach on a non-human primate (NHP) model.

• Cohort: 20 NHPs infected with a genetically barcoded isogenic library of Mtb. The groups included:
  • Mtb-only controls (TB).
  • Chronic SIV-infected animals (SIV+TB).
  • SIV-infected animals with virological suppression via ART (SIV+ART+TB).
• Sampling: Genomic DNA was extracted from 482 infected tissues (including lungs, thoracic lymph nodes, and extrapulmonary sites) collected at necropsy (10–12 weeks post-infection).
• Sequencing & Analysis:
  • Illumina NovaSeq S4 sequencing was performed.
  • Reads were mapped to a barcoded Mtb Erdman reference genome.
  • Variant Calling: Mutect2 was used to identify SNPs and indels.
  • Filtering: Variants were filtered for low frequency (<10%), low coverage, and sequencing artifacts (e.g., C-to-A transversions associated with heat damage during library prep).
  • In Vivo vs. In Vitro Discrimination: A critical step involved cross-referencing WGS data with pre-existing barcoding data. Mutations were classified as in vivo-derived only if they appeared in a subset of tissues infected by the same barcoded strain (indicating emergence during infection) rather than being present in all tissues of that strain (indicating pre-existing in the library).
• Metrics:
  • Mutation Rate: Calculated as unique mutational events normalized by infection time and tissue count (using a fixed generation time assumption).
  • Bacterial Burden: Quantified via Colony Forming Units (CFU) and Chromosomal Equivalents (CEQ).
  • Dissemination Mapping: Intrahost mutations were used as secondary "barcodes" to reconstruct dissemination networks alongside the primary genetic barcodes.

3. Key Contributions

• Unprecedented Scale: The study analyzed Mtb populations from nearly 500 distinct tissue sites across 20 animals, providing a high-resolution map of intrahost evolution.
• Differentiation of Immune Pressures: It distinguishes the specific evolutionary pressures exerted by SIV coinfection versus ART-suppressed SIV infection.
• Dissemination Reconstruction: It demonstrates that intrahost mutations can serve as secondary barcodes to infer complex, parallel dissemination networks, challenging the model of single-event radiation.
• Cross-Species Validation: It identifies a subset of NHP-derived mutations that have independently arisen and been transmitted in human clinical strains, validating the NHP model for studying human TB evolution.

4. Key Results

A. Divergent Mutational Trajectories by Treatment Group

• SIV+TB (No ART): These animals exhibited a significantly higher mutation rate compared to Mtb-only controls. This was driven by increased bacterial replication (higher CEQ and CFU) and the retention of deleterious mutations due to impaired immune clearance. However, they showed fewer oxidative damage-associated mutations compared to controls.
• SIV+ART+TB: Despite viral suppression, these animals showed a trend toward higher oxidative damage-associated mutations (specifically C>T/G>A transitions and C>A/G>T transversions) compared to Mtb-only controls. This suggests that ART does not fully restore the immune environment; instead, it may induce a dysregulated, heightened inflammatory response causing increased oxidative stress on the bacteria.
• Correlation: In SIV+ART+TB animals, there was a significant correlation between the prevalence of oxidative mutations and overall mutation rates, and these mutations appeared earlier in PET-CT detected granulomas.

B. Intrahost Dissemination Patterns

• Parallel Subnetworks: By integrating WGS variants with barcoding data, the authors reconstructed dissemination networks. They found that Mtb dissemination occurs via parallel subnetworks originating from different tissues, rather than a single "star" event where all dissemination stems from one early lesion.
• Directionality: The study inferred directional dissemination events, including instances where Mtb spread from the lung to lymph nodes and subsequently returned to the lung from extrapulmonary sites.

C. Functional Enrichment of Mutations

• Lipid Metabolism: Intrahost mutations were significantly enriched in genes involved in lipid metabolism and polyketide synthase (pks) pathways (e.g., pks7, pks8, pks12, mbtD).
• Human Relevance: These lipid metabolism genes were also enriched in human intrahost datasets (Liu et al. and Lieberman et al.).
• Clinical Transmission: 22 NHP-derived mutations were found in human clinical strains. Notably, a frameshift in pks7 and a missense mutation in rnj (associated with drug tolerance) appeared independently in multiple human infections and were successfully transmitted between individuals.
• Oxidative Signature: Mutations matching those found in human clinical strains were significantly enriched for C>T/G>A transitions, reinforcing the role of host oxidative immune pressure in driving Mtb diversification.

5. Significance and Implications

• Mechanistic Insight: The study reveals that HIV coinfection and ART treatment exert distinct evolutionary pressures on Mtb. SIV increases mutation rates via replication and retention, while ART (in the context of SIV) appears to increase oxidative stress on the bacteria, potentially driving specific mutational signatures.
• Metabolic Adaptation: The enrichment of mutations in lipid metabolism and pks genes suggests that Mtb actively adapts to the host's nutrient environment (specifically lipid catabolism and redox balancing) during early infection. This highlights lipid metabolism as a critical target for host-pathogen interaction.
• Model Validity: The finding that NHP-derived mutations are shared with human clinical isolates validates the SIV/NHP model as a robust system for studying the early evolutionary dynamics of TB, including the impact of comorbidities like HIV.
• Clinical Relevance: Understanding how ART alters the immune pressure on Mtb (shifting from replication-driven to oxidative-driven mutation) could inform strategies to improve TB outcomes in PLHIV on long-term therapy. It suggests that "virologic control" does not equate to a "restored immune environment" regarding TB control.

Limitations Noted: The study focuses on early infection (10-12 weeks), potentially missing late-emerging mutations. The 10% prevalence threshold may filter out low-frequency variants, and repetitive PE/PPE gene families were masked due to mapping difficulties. Additionally, the study does not capture inter-host transmission bottlenecks.